Active ingredientGadodiamideCat. No. P-G004-001CAS 131410-48-5Family · Pharmaceutical analytical standards
Gadodiamide
A gadolinium-based contrast agent for magnetic resonance imaging, approved in 1993: injected into a vein, it helps visualise blood vessels and lesions in the brain, spine and rest of the body. In 2017 the European Medicines Agency suspended its use. This family brings together the active ingredient and pharmacopoeial impurities.
Did you know?The gadolinium that makes it visible on MRI is named after the mineral gadolinite, which in turn honours the chemist Johan Gadolin, who first analysed it in 1794.
Go to the active ingredient →Active ingredientGadodiamideCat. No. P-G004-001CAS 131410-48-5
Pharmacopoeial impurityGadodiamide EP Impurity A Sodium SaltCat. No. P-G004-002
Pharmacopoeial impurityGadodiamide EP Impurity BCat. No. P-G004-003CAS 92923-64-3No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceGadodiamide CRSEDQM code Y0001875Family GadodiamideImpurityGadodiamide impurity A CRSEDQM code Y0001876Family GadodiamideImpurityGadodiamide impurity B CRSEDQM code Y0001877Family GadodiamideNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.